Showing results (1751-1760 of 1,792) with videos related to

Sort By:
Pageof 180
Trends in Ecology & Evolution|January 21, 2022
Freshwater salinisation: a research agenda for a saltier worldDavid Cunillera-Montcusí, Meryem Beklioğlu, Miguel Cañedo-Argüelles, et al.
Implementation Science : IS|August 14, 2020
Protocol for the 3HP Options Trial: a hybrid type 3 implementation-effectiveness randomized trial of delivery strategies for short-course tuberculosis preventive therapy among people living with HIV in UgandaJillian L Kadota, Allan Musinguzi, Juliet Nabunje, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|May 26, 2023
Understanding patient-level costs of weekly isoniazid-rifapentine (3HP) among people living with HIV in UgandaJ Sung, A Musinguzi, J L Kadota, et al.
Nature Communications|February 8, 2017
Hotspots of aberrant enhancer activity punctuate the colorectal cancer epigenomeAndrea J Cohen, Alina Saiakhova, Olivia Corradin, et al.
Water Research|March 6, 2025
Skyglow increases cyanobacteria abundance and organic matter cycling in lakesJeremy Fonvielle, Lukas Thuile Bistarelli, Yile Tao, et al.
Nature Methods|October 22, 2013
Metagenomic species profiling using universal phylogenetic marker genesShinichi Sunagawa, Daniel R Mende, Georg Zeller, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|September 3, 2016
Outbreak investigation for toxigenic Corynebacterium diphtheriae wound infections in refugees from Northeast Africa and Syria in Switzerland and Germany by whole genome sequencingD M Meinel, R Kuehl, R Zbinden, et al.
JAMA|May 16, 2019
Effect of Restriction of the Number of Concurrently Open Records in an Electronic Health Record on Wrong-Patient Order Errors: A Randomized Clinical TrialJason S Adelman, Jo R Applebaum, Clyde B Schechter, et al.
Plos Medicine|December 16, 2021
Completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness-implementation randomized trialFred C Semitala, Jillian L Kadota, Allan Musinguzi, et al.
Molecular Medicine (Cambridge, Mass.)|January 1, 1997
Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified riskP A Zimmerman, A Buckler-White, G Alkhatib, et al.
Pageof 180